Research programme: hearing and balance loss gene therapy - GenVec/Novartis
Alternative Names: Atonal gene therapy - GenVec/Novartis; Hearing loss gene therapy - GenVec/Novartis; math1 gene therapy - GenVec/Novartis; TherAtoH atonal therapy - GenVec/NovartisLatest Information Update: 04 Nov 2017
At a glance
- Originator Baylor College of Medicine
- Developer GenVec; Novartis
- Class Gene therapies
- Mechanism of Action Intercellular signalling peptide and protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ear disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ear disorders in USA (Otic, Infusion)
- 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
- 01 May 2014 Novartis plans a phase I/II trial for Hearing loss in USA (NCT02132130)